Strategies toward rheumatoid arthritis therapy; the old and the new
| Autor: | Mojtaba Abbasi, Mohammad Javad Mousavi, Saeed Aslani, Sirous Jamalzehi, Hamed Mohammadi, Maryam Hasanzadeh Bezvan, Reza Alimohammadi |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
musculoskeletal diseases
0301 basic medicine Oncology medicine.medical_specialty Physiology Clinical Biochemistry Mesenchymal Stem Cell Transplantation Epigenesis Genetic Etanercept Arthritis Rheumatoid 03 medical and health sciences 0302 clinical medicine Sulfasalazine Internal medicine medicine Adalimumab Humans Molecular Targeted Therapy Leflunomide Biological Products Anakinra business.industry Abatacept Cell Biology medicine.disease Infliximab Treatment Outcome 030104 developmental biology Pharmacogenetics Antirheumatic Agents 030220 oncology & carcinogenesis Rheumatoid arthritis Drug Therapy Combination business Signal Transduction medicine.drug |
| Zdroj: | Journal of Cellular Physiology. 234:10018-10031 |
| ISSN: | 1097-4652 0021-9541 |
| Popis: | Currently, medications used to treat rheumatoid arthritis (RA) are glucocorticoids (GCs) and nonsteroidal anti-inflammatory drugs (NSAIDs), predominantly used for controlling the pain and inflammation, disease-modifying antirheumatic drugs (DMARDs), administered as first-line medication for newly diagnosed RA cases, and biological therapies, used to target and inhibit specific molecules of the immune and inflammatory responses. NSAIDs and other GCs are effective in alleviating the pain, inflammation, and stiffness due to RA. DMARDs that are used for RA therapy are hydroxychloroquine, methotrexate, leflunomide, and sulfasalazine. The biological therapies, on the contrary, are chimeric anti-CD20 monoclonal antibody, rituximab, inhibitors of tumor necrosis factor-α (TNF-α) like etanercept, infliximab, and adalimumab, a recombinant inhibitor of interleukin-1 (IL-1), anakinra, and costimulation blocker, abatacept. Moreover, newly under evaluation biological therapies include new TNF-α inhibitors, JAK inhibitors, anti-interleukin-6-receptor monoclonal antibodies (mABs), and antibodies against vital molecules involved in the survival and development of functional B cells. The new strategies to treat RA has improved the course of the disease and most of the patients are successful in remission of the clinical manifestations if the diagnosis of the disease occur early. The probability of remission increase if the diagnosis happens rapidly and treat-to-target approach are implemented. In this review article, we have attempted to go through the treatment strategies for RA therapy both the routine ones and those which have been developed over the past few years and currently under investigation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text